-
公开(公告)号:US20120141502A1
公开(公告)日:2012-06-07
申请号:US13265332
申请日:2010-04-20
申请人: Eric Dixon , Rainer Blaesius , Stephen Simkins , Steven L. Knapp , George Brough , Karen Lenz , Johannes Schweizer , Peter Lu , David Garman , Jon Silver , Charles Mahoney , Chamorro Somoza Diaz-Sarmiento
发明人: Eric Dixon , Rainer Blaesius , Stephen Simkins , Steven L. Knapp , George Brough , Karen Lenz , Johannes Schweizer , Peter Lu , David Garman , Jon Silver , Charles Mahoney , Chamorro Somoza Diaz-Sarmiento
IPC分类号: A61K39/395 , A61P31/20 , C40B30/04 , C12Q1/70 , C40B40/10
CPC分类号: G01N33/5748 , C07K16/084 , C07K2317/33 , C07K2317/34 , C07K2317/76 , G01N33/56983 , G01N2333/025 , G01N2469/10
摘要: The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.
摘要翻译: 本发明提供了用于检测样品中至少一种HPV病毒株的E6蛋白的抗体组合物。 受试抗体可用于检测样品中的致癌HPV E6蛋白,并且抗体可用于多种诊断和治疗应用,包括诊断和治疗癌症的方法。 还提供了用于进行受试方法并含有目标抗体的试剂盒。 本发明还公开了产生特异性结合至少两种HPV病毒株的E6蛋白的氨基末端的抗体的方法。
-
公开(公告)号:US08536129B2
公开(公告)日:2013-09-17
申请号:US13186418
申请日:2011-07-19
申请人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
IPC分类号: A61K38/04
CPC分类号: A61K38/1787 , A61K38/07
摘要: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译: 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法,其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
公开(公告)号:US07585270B2
公开(公告)日:2009-09-08
申请号:US11950922
申请日:2007-12-05
申请人: Jon Doumbos , David Garman , Geoff W Richardson
发明人: Jon Doumbos , David Garman , Geoff W Richardson
IPC分类号: B09B3/00
CPC分类号: C04B9/00 , C04B28/105 , C04B28/30 , Y02W30/91 , C04B18/0463 , C04B40/0028 , C04B22/142 , C04B24/04 , C04B22/124 , C04B22/12 , C04B2103/0086
摘要: A method of incorporating a material in a settable binder is disclosed. The binder includes a source of caustic magnesium oxide. The method involves mixing the material with the binder, either as part of a slurry or for subsequent formation into a slurry, and then adding a setting agent to the slurry. The setting agent is added to enhance setting of the binder. The material can be a hazardous waste material or components thereof. The inventors have surprisingly discovered that when the setting agent is added after mixing of the material with the binder, that a superior setting of the material in the binder can be achieved. The settable composition can comprise only a caustic magnesium oxide binder and a setting agent for the binder, as the inventors have surprisingly discovered that there is no need for any other binding agents, thus providing a simpler binder composition and method of use.
摘要翻译: 公开了一种将材料掺入可固化的粘合剂中的方法。 粘合剂包括苛性氧化镁源。 该方法包括将材料与粘合剂混合,作为浆料的一部分或随后形成浆料,然后向浆料中加入固化剂。 添加固化剂以增强粘合剂的设置。 该材料可以是有害废物或其组分。 发明人惊奇地发现,当将材料与粘合剂混合后添加固化剂时,可以实现粘合剂中材料的优异设定。 本发明人惊奇地发现,不需要任何其它粘合剂,因此可提供更简单的粘合剂组合物和使用方法,可固化组合物可仅包含苛性氧化镁粘合剂和粘合剂固化剂。
-
公开(公告)号:US20120083449A1
公开(公告)日:2012-04-05
申请号:US13186418
申请日:2011-07-19
申请人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
CPC分类号: A61K38/1787 , A61K38/07
摘要: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译: 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法,其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
公开(公告)号:US08633160B2
公开(公告)日:2014-01-21
申请号:US12167852
申请日:2008-07-03
CPC分类号: G01N33/6896 , A61K38/06 , C12Q1/26 , G01N33/88 , G01N2500/00
摘要: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.
摘要翻译: 本发明涉及用于调节与同源配体的PDZ结构域相互作用的组合物。 还提供了评估和表征各种多肽的PDZ结构域相互作用的方法。
-
公开(公告)号:US08008253B2
公开(公告)日:2011-08-30
申请号:US12165983
申请日:2008-07-01
申请人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
IPC分类号: A61K38/04
CPC分类号: A61K38/1787 , A61K38/07
摘要: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译: 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法,其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
公开(公告)号:US20090062213A1
公开(公告)日:2009-03-05
申请号:US12167852
申请日:2008-07-03
CPC分类号: G01N33/6896 , A61K38/06 , C12Q1/26 , G01N33/88 , G01N2500/00
摘要: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.
摘要翻译: 本发明涉及用于调节与同源配体的PDZ结构域相互作用的组合物。 还提供了评估和表征各种多肽的PDZ结构域相互作用的方法。
-
公开(公告)号:US20090036376A1
公开(公告)日:2009-02-05
申请号:US12165983
申请日:2008-07-01
申请人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人: Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
CPC分类号: A61K38/1787 , A61K38/07
摘要: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译: 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法,其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
-
-
-
-
-
-